bsm-51578M

- DATASHEET -

[Primary Antibody]

BCL10 Mouse mAb



www.bioss.com.cn sales@bioss.com.cn techsupport@bioss.com.cn 400-901-9800

> **IHC-P** (1:100-500) IHC-F (1:100-500) **IF** (1:100-500) Flow-Cyt (1:50-100)


Subcellular Location: Cell membrane ,Cytoplasm

Host: Mouse	lsotype: lgG1, k	Applications: WB (1:500-2000)
Clonality: Monoclonal	CloneNo.: G56	IHC-P (1:100-500) IHC-F (1:100-500)
GenelD: 8915	SWISS: 095999	IF (1:100-500)
Target: BCL10		Flow-Cyt (1:50-10
Immunogen: KLH conjugated synthetic peptide derived from human BCL10: 1-130/233.		Reactivity: Human, Mouse
Purification: affinity purified by P	rotein G	
Concentration: 1mg/ml		Predicted MW.: ^{26 kDa}
Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50%		


Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background: This gene was identified by its translocation in a case of mucosaassociated lymphoid tissue (MALT) lymphoma. The protein encoded by this gene contains a caspase recruitment domain (CARD), and has been shown to induce apoptosis and to activate NF-kappaB. This protein is reported to interact with other CARD domain containing proteins including CARD9, 10, 11 and 14, which are thought to function as upstream regulators in NF-kappaB signaling. This protein is found to form a complex with MALT1, a protein encoded by another gene known to be translocated in MALT lymphoma. MALT1 and this protein are thought to synergize in the activation of NF-kappaB, and the deregulation of either of them may contribute to the same pathogenetic process that leads to the malignancy. [provided by RefSeq, Jul 2008]


- VALIDATION IMAGES




25 ug total protein per lane of various lysates (see on figure) probed with Bcl10 monoclonal antibody, unconjugated (bsm-51578M) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.



Paraformaldehyde-fixed, paraffin embedded Human Tonsil; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with BCL10 Monoclonal Antibody, Unconjugated(bsm-51578M) at 1:200 overnight at 4°C, followed by conjugation to the bs-40296G-HRP and DAB (C-0010) staining.



Paraformaldehyde-fixed, paraffin embedded Human Gastric Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with BCL10 Monoclonal Antibody, Unconjugated(bsm-51578M) at 1:200 overnight at 4°C, followed by conjugation to the bs-40296G-HRP and DAB (C-0010) staining.



Blank control:Hela. Primary Antibody (green line): Mouse Anti-BCL10 antibody (bsm-51578M) Dilution: 1:100; Secondary Antibody : Goat antimouse IgG-FITC Dilution: 0.5ug/Test. Protocol

The cells were fixed with 4% PFA (10min at room temperature) and then permeabilized with 90% ice-cold methanol for 20 min at -20°C. The cells were then incubated in 5%BSA to block nonspecific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.